Kevin Carlton

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 28 papers. Top paper: “A Monoclonal Antibody for Malaria Prevention”.

A Monoclonal Antibody for Malaria Prevention

New England Journal of Medicine(2021)10.1056/nejmoa2034031

N/A

5.5DataRank · unranked

160 citations

Nina M. Berkowitz, Azza H. Idris, Emily E. Coates, LaSonji A. Holman, Floreliz Mendoza +33 more

Safety and Efficacy of a Monoclonal Antibody against Malaria in Mali

New England Journal of Medicine(2022)10.1056/nejmoa2206966

N/A

3.9DataRank · unranked

127 citations

Aïssata Ongoïba, Anne C Preston, Sara A. Healy, Safiatou Doumbo, Didier Doumtabé +27 more

Safety and immunogenicity of a ferritin nanoparticle H2 influenza vaccine in healthy adults: a phase 1 trial

Nature Medicine(2022)10.1038/s41591-021-01660-8

N/A

3.6DataRank · unranked

165 citations

Grace Chen, Cristina Carter, Michelle C. Crank, Thuy Nguyen, Maria Claudia Burgos Florez +70 more

Low-Dose Subcutaneous or Intravenous Monoclonal Antibody to Prevent Malaria

New England Journal of Medicine(2022)10.1056/nejmoa2203067

N/A

3.6DataRank · unranked

125 citations

Azza H. Idris, Nina M. Berkowitz, Myra Happe, Martin R. Gaudinski, Christian Buettner +42 more

Subcutaneous Administration of a Monoclonal Antibody to Prevent Malaria

New England Journal of Medicine(2024)10.1056/nejmoa2312775

N/A

2.6DataRank · unranked

84 citations

Aïssata Ongoïba, Anne C Preston, Sara A. Healy, Zonghui Hu, Jeff Skinner +38 more

Safety, tolerability, and immunogenicity of the respiratory syncytial virus prefusion F subunit vaccine DS-Cav1: a phase 1, randomised, open-label, dose-escalation clinical trial

The Lancet Respiratory Medicine(2021)10.1016/s2213-2600(21)00098-9

N/A

2.5DataRank · unranked

67 citations

Kaitlyn M. Morabito, Emily Phung, Michelle C. Crank, Pamela Costner, LaSonji A. Holman +74 more

An influenza hemagglutinin stem nanoparticle vaccine induces cross-group 1 neutralizing antibodies in healthy adults

Science Translational Medicine(2023)10.1126/scitranslmed.ade4790

N/A

1.9DataRank · unranked

96 citations

Amelia R. Hofstetter, Katherine V. Houser, Seemal F. Awan, Grace Chen, Maria Claudia Burgos Florez +95 more

Low-dose intravenous and subcutaneous CIS43LS monoclonal antibody for protection against malaria (VRC 612 Part C): a phase 1, adaptive trial

The Lancet Infectious Diseases(2023)10.1016/s1473-3099(22)00793-9

N/A

1.2DataRank · unranked

41 citations

Andrea A. Berry, Kaitlin Mason, Azza H. Idris, Mark O’Callahan, Myra Happe +95 more

Safety and immunogenicity of a trivalent virus-like particle vaccine against western, eastern, and Venezuelan equine encephalitis viruses: a phase 1, open-label, dose-escalation, randomised clinical trial

The Lancet Infectious Diseases(2022)10.1016/s1473-3099(22)00052-4

N/A

1.1DataRank · unranked

39 citations

Srilatha Edupuganti, Grace Chen, Myra Happe, Larisa Strom, Alicia T. Widge +67 more

Safety and pharmacokinetics of escalating doses of neutralising monoclonal antibody CAP256V2LS administered with and without VRC07-523LS in HIV-negative women in South Africa (CAPRISA 012B): a phase 1, dose-escalation, randomised controlled trial

The Lancet HIV(2023)10.1016/s2352-3018(23)00003-6

N/A

1.1DataRank · unranked

40 citations

Nigel Garrett, Edmund V. Capparelli, Farzana Osman, Nonhlanhla N. Mkhize, Ishana Harkoo +16 more

Phase 1 trial evaluating safety and pharmacokinetics of HIV-1 broadly neutralizing mAbs 10E8VLS and VRC07-523LS

JCI Insight(2024)10.1172/jci.insight.175375

N/A

0.404DataRank · unranked

7 citations

Amarendra Pegu, Larisa Strom, Cristina Carter, Cynthia S. Hendel, LaSonji A Holman +32 more

Safety and pharmacokinetics of N6LS, a broadly neutralising monoclonal antibody for HIV: a phase 1, open-label, dose-escalation study in healthy adults

The Lancet HIV(2025)10.1016/s2352-3018(25)00041-4

N/A

0.335DataRank · unranked

8 citations

Katherine V. Houser, Martin R. Gaudinski, Alicia T. Widge, Seemal F. Awan, Cristina Carter +95 more

Extended safety and tolerability of subcutaneous CAP256V2LS and VRC07-523LS in HIV-negative women: study protocol for the randomised, placebo-controlled double-blinded, phase 2 CAPRISA 012C trial

BMJ Open(2023)10.1136/bmjopen-2023-076843

N/A

0.104DataRank · unranked

1 citations

Nigel Garrett, Disebo Potloane, Izukanji Sikazwe, Edmund V. Capparelli, Ishana Harkoo +22 more

Rapid loss of activity but not serum concentration in a passive infusion clinical trial of an HIV neutralizing antibody

medRxiv(2025)10.1101/2025.09.04.25334949

N/A

0DataRank · unranked

1 citations

Nonhlanhla N. Mkhize, Leonid Serebryannyy, Tandile Hermanus, Prudence Kgagudi, Haajira Kaldine +15 more

Preclinical Development of a Fusion Peptide Conjugate as an HIV Vaccine Immunogen

Scientific Reports(2020)10.1038/s41598-020-59711-y

N/A

0DataRank · unranked

57 citations

Wing‐Pui Kong, Gwo‐Yu Chuang, Mridul Ghosh, Krishana Gulla, Sijy O’Dell +69 more

Multi-attribute monitoring (MAM) methodology for glycosylated subunit vaccines

Scientific Reports(2025)10.1038/s41598-025-24922-8

N/A

0DataRank · unranked

0 citations

Lisa M. Jenkins, Nathan Barefoot, Darielys Maldonado, Jeremy J. Wolff, Yanhong Yang +13 more

A matrix of structure-based designs yields improved VRC01-class antibodies for HIV-1 therapy and prevention

mAbs(2021)10.1080/19420862.2021.1946918

N/A

0DataRank · unranked

25 citations

Mangaiarkarasi Asokan, Jason Gorman, Baoshan Zhang, Qingbo Liu, Mark K. Louder +12 more

Safety and Pharmacokinetics of Monoclonal Antibodies VRC07-523LS and PGT121 Administered Subcutaneously for Human Immunodeficiency Virus Prevention

The Journal of Infectious Diseases(2022)10.1093/infdis/jiac041

N/A

0DataRank · unranked

36 citations

Nigel Garrett, Edmund V. Capparelli, Farzana Osman, Ishana Harkoo, Nonhlanhla Yende‐Zuma +17 more

Engineering of HIV-1 neutralizing antibody CAP256V2LS for manufacturability and improved half life

Scientific Reports(2022)10.1038/s41598-022-22435-2

N/A

0DataRank · unranked

14 citations

Deepika Gollapudi, Jason Gorman, Sijy O’Dell, Leland F. Damron, Krisha McKee +23 more

Tyrosine O-sulfation proteoforms affect HIV-1 monoclonal antibody potency

Scientific Reports(2022)10.1038/s41598-022-12423-x

N/A

0DataRank · unranked

15 citations

Nicole A. Doria‐Rose, Nicole A. Schneck, Vera B. Ivleva, Brad Tippett, William R. Shadrick +17 more

Analytical characterization of broadly neutralizing antibody CAP256LS heavy chain clipping during manufacturing development

Biotechnology Progress(2022)10.1002/btpr.3296

N/A

0DataRank · unranked

2 citations

Erwin Rosales‐Zavala, Vera B. Ivleva, Yanhong Yang, Yile Li, Sarah O’Connell +8 more

A multispecific antibody prevents immune escape and confers pan-SARS-CoV-2 neutralization

bioRxiv (Cold Spring Harbor Laboratory)(2022)10.1101/2022.07.29.502029

N/A

0DataRank · unranked

5 citations

Ronnie R. Wei, Lingshu Wang, Amarendra Pegu, Chih‐Jen Wei, Olamide K. Oloniniyi +36 more

Engineering of HIV-1 neutralizing antibody CAP256V2LS for manufacturability and improved half life

Research Square(2022)10.21203/rs.3.rs-1534769/v1

N/A

0DataRank · unranked

0 citations

Deepika Gollapudi, Jason Gorman, Sijy O’Dell, Leland F. Damron, Krisha McKee +23 more

Bispecific antibody CAP256.J3LS targets V2-apex and CD4-binding sites with high breadth and potency

mAbs(2023)10.1080/19420862.2023.2165390

N/A

0DataRank · unranked

14 citations

Jason Gorman, Young Do Kwon, Amarendra Pegu, Cara W. Chao, Tracy Liu +23 more

Phase 1 dose-escalation trial evaluating a group 2 influenza hemagglutinin stabilized stem nanoparticle vaccine

npj Vaccines(2024)10.1038/s41541-024-00959-0

N/A

0DataRank · unranked

21 citations

Amelia R. Hofstetter, Pamela Costner, LaSonji A Holman, Cynthia S. Hendel, Alicia T. Widge +95 more

Mosaic quadrivalent influenza vaccine single nanoparticle characterization

Scientific Reports(2024)10.1038/s41598-024-54876-2

N/A

0DataRank · unranked

12 citations

Maria Traver, Nathan Barefoot, Tyler Stephens, Casper Alabanza, Javier Manzella‐Lapeira +13 more

Population pharmacokinetics of weight-based compared with fixed dosing of CAP256V2LS, a broadly neutralizing antibody for HIV prevention in women

Journal of Antimicrobial Chemotherapy(2025)10.1093/jac/dkaf181

N/A

0DataRank · unranked

1 citations

Martin Béliveau, Roberto Heredia‐Ortiz, Farzana Osman, Marothi Letsoalo, Nigel Garrett +13 more

Hyaluronidase-enhanced subcutaneous delivery of bNAbs: a phase 1 randomized controlled clinical trial in HIV-uninfected women

Nature Communications(2025)10.1038/s41467-025-63051-8

N/A

0DataRank · unranked

1 citations

Farzana Osman, Martin Béliveau, Roberto Heredia‐Ortiz, Kevin Carlton, Jennifer Wang +10 more